Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug cocktail shows promise for Tough-to-Treat colorectal cancer

NCT ID NCT07150247

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 28 times

Summary

This study is for adults with a specific genetic form of advanced colorectal cancer (BRAF V600E) that has worsened after standard treatments. Researchers want to see if adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemotherapy and a targeted drug can shrink tumors and control the cancer longer. About 20 participants will receive the combination every two weeks and be closely monitored for safety and response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAF V600 COLORECTAL CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Sun Yat-sen University Cancer Center

    RECRUITING

    Guangzhou, Guangdong, 510060, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.